Moderna, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRNA research report →
Range $25 – $305
Price Chart
About the company
Moderna, Inc. , a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
- CEO
- Stéphane Bancel
- IPO
- 2018
- Employees
- 4,700
- HQ
- Cambridge, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a long-term recovery regime, trading well above its 200-day average after a deep 52-week range. That backdrop still leaves it far below the yearly high, so the setup is constructive but not fully repaired.
Street sentiment is cautious-to-neutral, with a 3.087 consensus and a Hold call overall. The average target sits below the current share price, and recent changes have been mixed: Piper Sandler and JPMorgan raised targets, while William Blair cut its rating to Market Perform and Citi/UBS kept a bearish tilt.
Earnings have been choppy but recently improved, with the latest quarter delivering a 134.5% EPS beat after a string of uneven results. Analysts still expect losses ahead, with 2027 EPS at -4.33038 and 2028 at -2.53214, so shareholders should watch whether margin recovery can outpace the still-negative earnings path.
Recent insider activity leans negative on discretionary trading, led by President Stephen Hoge’s repeated sales in October and November. The other large entries are awards, exempt transactions, and a gift, which are mostly administrative noise; the signal is the cluster of open-market selling rather than buying.
Profitability remains weak, with a -80.79% operating margin and a -110.46% net margin. Revenue is still growing at 29.2% year over year, but cash burn remains heavy at -$1.873 billion in operating cash flow and -$1.681 billion in free cash flow for 2025.
Moderna still screens as a premium biotech name on scale and cash, with $5.799 billion in cash and net cash of $4.494 billion. The tradeoff is valuation: the stock carries a negative earnings profile and a richer setup than peers that already have clearer profitability.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.90B
- P/E
- -27.54
- Fwd P/E
- 282.69
- PEG
- -2.83
- P/S
- 31.25
- P/B
- 11.44
- EV/EBITDA
- -33.35
- Div Yield
- 0.00%
- Gross Margin
- 28.00%
- Op Margin
- -116.04%
- Net Margin
- -110.46%
- ROE
- -37.62%
- ROIC
- -25.61%
Latest fiscal year · YoY change
- Revenue
- $1.94B-39.2%
- Gross Profit
- $1.08B-38.0%
- Op Income
- $-3,074,000,000
- Net Income
- $-2,822,000,000+20.8%
- EPS
- $-7.26+21.7%
- OCF Growth
- +37.6%
- FCF Growth
- +49.1%
- 52W High
- $280.80
- 52W Low
- $22.28
- 50D MA
- $206.87
- 200D MA
- $99.64
- Beta
- 0.90
- RSI (14)
- 46
- Avg Volume
- 17.73M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Moderna beat on revenue and profit in Q3, raised 2026 revenue guidance, and highlighted major oncology progress led by positive Phase 3 melanoma data for Intismeran.· November 6, 2026
- Q3 revenue was $1.3 billion, up 29% year over year, with net income of $162 million and diluted EPS of $0.38 versus a loss of $0.51 last year.
- Management raised full-year 2026 revenue growth guidance to 15% to 25% from up to 10%, citing stronger-than-expected U.S. and international vaccine demand.
- The company ended Q3 with $8 billion in cash and investments, helped by $2.6 billion of net proceeds from a convertible note and capped call transaction.
- Intismeran posted positive Phase 3 melanoma data, with a 42% reduction in recurrence or death in the primary analysis and 49% in the MITT analysis.
- Norovirus phase 3 did not meet early success criteria, and Moderna said it will not enroll an additional winter cohort while it consults regulators.
Moderna reported Q3 revenue of $1.3 billion, up 29% year over year, with cost of sales of $318 million (24% of revenue), R&D expense of $583 million, SG&A of $282 million, net income of $162 million, and diluted EPS of $0.38 versus a loss per share of $0.51 a year ago. Cash and investments ended the quarter at $8 billion, up from $6.9 billion at the end of Q2, driven by $2.6 billion of net proceeds from a convertible note transaction, partly offset by a $950 million litigation settlement payment and working-capital seasonality. For 2026, Moderna raised its revenue growth framework to 15% to 25%, kept cost of sales at $1.7 billion (including the $900 million litigation charge), lowered R&D by $200 million to $2.7 billion, kept SG&A at about $1 billion, lowered CapEx to $200 million, and now expects year-end cash and investments of $8.1 billion to $8.3 billion.
Stéphane Bancel framed the quarter as evidence that Moderna can grow commercially while staying disciplined on costs and capital. He highlighted FDA approval of mFLUSIVA as the company’s fifth approved product, positive Phase 3 melanoma data for Intismeran, and the $3 billion convertible financing as key milestones that strengthen the balance sheet. His tone was upbeat and focused on execution, with emphasis on expanding the respiratory franchise and advancing oncology as a major strategic priority.
James Mock emphasized stronger-than-expected U.S. and international sales, noting that both markets outperformed in Q3 due to demand, execution, and shipment timing. He said cost discipline continued, with R&D down 27% year over year to $583 million and SG&A up only 5% to $282 million, while cash and investments rose to $8 billion. On the 2026 framework, he pointed to higher revenue growth, lower R&D, unchanged SG&A, flat taxes, lower CapEx, and improved cash outlook, while noting that the $8.1 billion to $8.3 billion cash target includes the convertible proceeds.
Analysts focused on Intismeran’s melanoma data, the RCC program, the BLA timeline, and how the company thinks about pricing and regulatory strategy. Management said the BLA submission is targeted for this year and approval is hoped for next year, while pricing is still premature and will be tied to value creation. On RCC, management said the study is event-driven, could read out late this year or early next year, and a positive result could be practice-informing or potentially support FDA discussions, but they would not go beyond that. They also said the norovirus program will not add another winter cohort after missing early success criteria, and future steps will depend on discussions with health authorities.
The call showed stronger commercial momentum than expected, with revenue growth broadening across the U.S. and international markets and management raising 2026 guidance. Moderna also ended the quarter with a stronger cash position and reduced cash cost targets. On the pipeline, the company pointed to a major oncology inflection point: positive Phase 3 melanoma data for Intismeran, ongoing expansion across multiple tumor types, and upcoming catalysts in RCC, BLA submission, ASH, and PA.
The biggest clinical risk is that norovirus missed early success criteria and the path forward is now uncertain pending regulator discussions. Intismeran still faces execution risk because the BLA has not yet been filed, the RCC readout is still pending, and management declined to give detailed guidance on statistical thresholds or disclosure plans. There is also uncertainty around future U.S. approval timing for the flu/COVID combination vaccine and around how much of the current international revenue strength is durable versus timing-related.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.3%
- Shares Outstanding
- 404.62M
- Float Shares
- 377.36M
of shares held by institutions
870 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MRNA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Oct 20, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Sell | Sep 24, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Sell | Aug 19, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | Aug 19, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 25, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Feb 25, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Jan 15, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 58.96M | ▲ 7.10M |
| Vanguard Group Inc | 41.58M | ▲ 399.49K |
| Blackrock, Inc. | 27.80M | ▼ 2.80M |
| Vanguard Capital Management LLC | 23.91M | ▲ 705.67K |
| Capital World Investors | 22.64M | ▲ 361.96K |
| Vanguard Portfolio Management LLC | 15.78M | ▲ 199.88K |
| State Street Corp | 15.47M | ▼ 254.28K |
| Baillie Gifford & Co | 11.44M | ▼ 6.77M |
| Geode Capital Management, LLC | 10.24M | ▲ 534.11K |
| Two Sigma Advisers, LP | 7.73M | ▲ 956.80K |
| Price T Rowe Associates Inc | 7.62M | ▲ 2.03M |
| Theleme Partners Llp | 6.66M | ▼ 1.40M |
Held by 1,545 ETFs
Biggest fund positions in MRNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Hoge Stephen | other | 76,453 |
| Nov 16, 26 | Hoge Stephen | sell | 39,160 |
| Nov 17, 26 | Hoge Stephen | other | 76,452 |
| Nov 17, 26 | Hoge Stephen | sell | 33,976 |
| Nov 17, 26 | Hoge Stephen | sell | 5,082 |
| Nov 17, 26 | Hoge Stephen | sell | 157 |
| Nov 16, 26 | Hoge Stephen | other | 400,000 |
| Nov 16, 26 | Hoge Stephen | other | 76,453 |
| Nov 17, 26 | Hoge Stephen | other | 76,452 |
| Nov 5, 26 | Andres Juan | other | 16,955 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MRNA coverage
Recent articles, reports, and earnings notes.

Moderna (MRNA): Oncology Could Replace the COVID Franchise
Moderna is a high-risk transition story as COVID revenue fades, but a strong Phase 3 melanoma result and a larger cash cushion keep the long-term thesis alive. The stock looks like a Hold while investors wait to see whether respiratory vaccines and oncology can drive durable earnings.

Moderna, Inc. (MRNA) drops 6.8% after earnings rally
Moderna, Inc. (MRNA) drops after a strong post-earnings run, giving back part of its recent gains. The move looks driven by profit-taking rather than a new negative catalyst, even after the company posted a sharp earnings beat and raised its outlook.

Moderna, Inc. (MRNA) drops 6.3% after earnings rally
Moderna, Inc. (MRNA) drops after a strong post-earnings run as investors take profits following a surprise Q3 beat, raised guidance, and a higher analyst target. The stock’s pullback looks more like a valuation reset than a fresh business setback.
Want a deeper read on MRNA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes
fool.com · Nov 20
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
fool.com · Nov 20
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
zacks.com · Nov 19
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
fool.com · Nov 19
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
zacks.com · Nov 18
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
marketbeat.com · Nov 18
Banco Santander S.A. Sells 30,065 Shares of Moderna, Inc. $MRNA
defenseworld.net · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice